พบ "Public health policy"ทั้งหมด 1,226 ผลลัพธ์
DAAs ยาใหม่รักษาตับอักเสบซีได้ดีกว่าเดิม แต่แพงกว่าเดิม และยังขาดข้อมูลความคุ้มค่า
การติดเชื้อไวรัสตับอักเสบซีอาจนําไปสู่ภาวะตับแข็งและมะเร็งตับได้ ปัจจุบันประเทศไทยไม่มีวัคซีนสําหรับป้องกันไวรัสตับอักเสบซี แต่เน้นที่การป้องกัน วินิจฉัย และรักษาเท่านั้น โดยมียา pegylated-interferon (เพ็คกิเลตอินเตอร์เฟอรอน) และ ribavirin (ไรบาวิริน) เรียกรูปแบบการใช้ยาว่า PR เป็นยาสูตรมาตรฐานในการ
Criteria for priority setting of HIV/AIDS interventions in Thailand: a discrete choice experiment. (2010)
Criteria for priority setting of HIV/AIDS interventions in Thailand: a discrete choice experiment
Sitaporn Youngkong*1,2, Rob Baltussen*1, Sripen Tantivess*2, Xander Koolman*3 and Yot Teerawattananon*2
1 Nijmegen International Center for Health Systems Research and Education (NICHE), Department of
COVID-19 Vaccination Policy Research and Decision Support Initiative in Asia (CORESIA): a regional study on vaccination certificates
As countries being their COVID-19 vaccinationation campaigns, an increasing number of public and private sectors in many settings are considering the introduction of COVID-19 vaccination certificates or similar instruments as a safe passage into the new normal. By facilitating the resumption of travel and economic activities, they can play an essen
COVID-19 Multi-Model Comparison Consortium (CMCC)
The CMCC aims to enhance the informed use of COVID-19 models in policy making, by providing end users (with focus on LMICs) with an accessible overview of the aims, capabilities and limits of the existing COVID-19 models, how projections differ and what the models’ key assumptions/drivers are. The CMCC is convened by BMGF, the Centers for Disease
Coverage Decisions and the Court: A Public Health Perspective on Glucosamine Reimbursement in Thailand (2016)
Sripen Tantivess & Viroj Tangcharoensathien
Abstract
Thailand achieves universal health coverage through the introduction of 3 benefit schemes: the Civil Servant Medical Benefit Scheme (CSMBS), Social Security Scheme, and Universal Coverage Scheme. The primary benefit package of these sche
Cost–utility and budget impact analysis of tocilizumab for the treatment of refractory systemic juvenile idiopathic arthritis in Thailand
ABSTRACT
Objectives: This study aimed to analyse the cost–utility and budget impact of adding tocilizumab to the standard treatment for patients with refractory systemic juvenile idiopathic arthritis (sJIA) in Thailand.
Design: Economic evaluation using a decision-analytical model.
Setting:
Cost-utility analysis of great saphenous vein ablation with radiofrequency, foam and surgery in the emerging health-care setting of Thailand (2015)
Boonying Siribumrungwong1, Pinit Noorit2,
Chumpon Wilasrusmee3, Pattara Leelahavarong4,
Ammarin Thakkinstian5 and Yot Teerawattananon4
Abstract
Objectives: To conduct economic evaluations of radiofrequency ablation, ultrasound-guided foam sclerotherapy and surgery for great saphenous vein ab
Cost-utility analysis of adjuvant chemotherapy in patients with stage III colon cancer in Thailand. (2014)
Background: In Thailand, there has been no economic evaluation study of adjuvant chemotherapy for stage III colon cancer patients after resection. Objective: This study aims to evaluate the cost-utility of all chemotherapy regimens currently used in Thailand compared with the adjuvant 5-fluorouracil
10 / หน้า